Moderna's stock jumped 11% with no new company news, driven by strong retail sentiment and trading momentum rather than fundamentals. Meanwhile, BioNTech rose only 2%, lagging behind both Moderna and the broader biotech sector, highlighting a growing divergence between the two mRNA-focused companies. Moderna has surged 371% year-to-date, vastly outperforming BioNTech's 19% gain and the biotech ETF's 35% rise. Investors are advised to manage position sizes carefully given the speculative nature of Moderna's recent rally and the clear decoupling of these two stocks despite sharing the same mRNA platform.
Merck shares have risen 45% year-to-date, driven by strong sales of its KEYTRUDA drug and upcoming regulatory milestones. Between September and October, Merck faces several FDA decision deadlines for new drug applications, including WINREVAIR and WEL...
Jim Cramer highlighted a market rotation away from tech and data center stocks toward enterprise software and pharmaceuticals, driven by political opposition to data center construction and bond market volatility. Software companies like ServiceNow, ...
Moderna shares fell 7% to $135.22 following a sharp rise to a record $176.66, as traders took profits after a 392% gain year-to-date. The pullback is orderly with no new company updates; the recent rally was driven by positive phase 3 melanoma trial ...
